We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
-0.47%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.52B
AUM Growth
-$648M
Cap. Flow
+$87.1M
Cap. Flow %
1.58%
Top 10 Hldgs %
32.16%
Holding
158
New
15
Increased
26
Reduced
36
Closed
15

Top Buys

Rank Stock Value
1
SVA
Sinovac Biotech, Ltd
SVA
+$349M
2
PGNY icon
Progyny
PGNY
+$22.4M
3
XENE icon
Xenon Pharmaceuticals
XENE
+$19.5M
4
TVTX icon
Travere Therapeutics
TVTX
+$19.4M
5
IONS icon
Ionis Pharmaceuticals
IONS
+$17.1M

Top Sells

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$76.7M
2
PFE icon
Pfizer
PFE
+$59.2M
3
IOVA icon
Iovance Biotherapeutics
IOVA
+$50.3M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$40.2M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$34.3M

Sector Composition

Rank Sector Weight
1 Healthcare 97.72%
2 Miscellaneous 2.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CRVS icon
101
Corvus Pharmaceuticals
CRVS
$1.1B
$6.88M 0.12%
6,943,654
– –
LUNG icon
102
Pulmonx
LUNG
$79.5M
$6.4M 0.12%
435,000
– –
SRRK icon
103
Scholar Rock
SRRK
$6.31B
$5.91M 0.11%
+1,076,540
New +$7.73M
HELP
104
Cybin Inc
HELP
$994M
$5.89M 0.11%
276,955
– –
HARP
105
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$5.8M 0.11%
303,951
– –
MIRM icon
106
Mirum Pharmaceuticals
MIRM
$6.28B
$5.44M 0.1%
279,500
+252,500
+935% +$5.96M
ELVN icon
107
Enliven Therapeutics
ELVN
$3.99B
$5.35M 0.1%
1,096,642
– –
NTRA icon
108
CALL
Natera
NTRA
$47.4B
$5.32M 0.1%
150,000
– –
IMCR icon
109
Immunocore
IMCR
$1.68B
$4.89M 0.09%
131,100
+3,000
+2% +$97.4K
CALC icon
110
CalciMedica
CALC
$13.7M
$4.54M 0.08%
59,476
– –
VOR icon
111
Vor Biopharma
VOR
$1.37B
$4.14M 0.08%
41,667
– –
BNR
112
Burning Rock Biotech
BNR
$130M
$4.04M 0.07%
138,980
-6,260
-4% -$280K
APLT
113
DELISTED
Applied Therapeutics
APLT
$4.03M 0.07%
+4,250,000
New +$6.96M
ACHL
114
DELISTED
Achilles Therapeutics
ACHL
$3.99M 0.07%
1,584,845
– –
CTMX icon
115
CytomX Therapeutics
CTMX
$697M
$3.89M 0.07%
2,124,975
– –
NVAX icon
116
CALL
Novavax
NVAX
$1.58B
$3.86M 0.07%
+75,000
New +$3.88M
CLDX icon
117
Celldex Therapeutics
CLDX
$3.08B
$3.04M 0.06%
112,700
-293,400
-72% -$8.52M
LOGC
118
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$2.97M 0.05%
8,466,783
– –
AFIB
119
DELISTED
Acutus Medical Inc
AFIB
$2.97M 0.05%
2,648,386
– –
DNTH icon
120
Dianthus Therapeutics
DNTH
$6.02B
$2.7M 0.05%
140,685
– –
ABCL icon
121
CALL
AbCellera Biologics
ABCL
$3.62B
$2.66M 0.05%
+250,000
New +$2.12M
IMDX
122
Insight Molecular Diagnostics
IMDX
$137M
$2.55M 0.05%
141,890
-32,800
-19% -$746K
TARA icon
123
Protara Therapeutics
TARA
$231M
$2.43M 0.04%
830,641
– –
LENZ
124
LENZ Therapeutics
LENZ
$142M
$2.33M 0.04%
121,202
-102,485
-46% -$2.28M
NMTR
125
DELISTED
9 Meters Biopharma
NMTR
$2.22M 0.04%
425,286
-88,508
-17% -$834K
3 4
5
6 7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q2 2022 Portfolio in Review

As of Q2 2022, OrbiMed held 158 positions worth $5.52B, down 11% from $6.17B the previous quarter. Its ten largest holdings account for 32% of the portfolio.

OrbiMed's Q2 2022 filing shows 15 new, 26 increased, 36 reduced and 15 closed positions. Its largest new stake was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M. The largest sale was DexCom, an estimated $76.7M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 98% a quarter earlier, followed by Miscellaneous.

  • OrbiMed's largest Q2 2022 buy was Sinovac Biotech, Ltd: 2,718,735 shares worth $350M.
  • OrbiMed added most to Xenon Pharmaceuticals in Q2 2022, an estimated $19.5M increase.
  • OrbiMed's biggest Q2 2022 reduction was Pfizer, cutting an estimated $59.2M.
  • OrbiMed fully exited DexCom in Q2 2022, selling an estimated $76.7M.
  • OrbiMed's ten largest holdings make up 32% of its $5.52B portfolio in Q2 2022.
  • OrbiMed opened 15 new positions and closed 15 in Q2 2022.
  • OrbiMed's portfolio value fell 11% quarter-over-quarter to $5.52B.

Based on OrbiMed's 13F filing for Q2 2022, filed 15 Aug 2022.